JAMA articles cast doubt over healthcare technology

Share this article:

An article published in today's issue of the Journal of the American Medical Association (JAMA) found 22 ways a computer system for physicians could increase the risk of medication errors. The JAMA article said most of the problems were created by poorly designed software that too often ignored how doctors and nurses work in a hospital setting.
Researchers said the likelihood of errors increased because information on patients' medications was scattered throughout the computer system. For example, to find a single patients' medication, a physician might have to browse up to 20 screens of information, researchers said.
Among the causes of error listed were patient names' being grouped together confusingly in tiny print, drug dosages that seem arbitrary and computer crashes.
Another article in today's JAMA examined 100 trials of computer systems intended to assist physicians in diagnosing and treating patients. The article said most of the positive assessment of clinical decision support systems came from technologists who played a role in designing the systems.
"In fact 'grading oneself' was the only factor that was consistently associated with good evaluations," JAMA's editorial titled "Still Waiting for Godot," said.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...